SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: the eagle who wrote (723)2/21/1998 11:52:00 AM
From: David Cathcart  Read Replies (1) of 1826
 
Eagle,

<<do we have competition for 114 either on the market or in development?>>

The on-the-market competition for MGI-114 is every therapy (e.g. the drug Taxol), or combination of therapies, that is presently used to treat solid tumors. There is plenty of competition out there but Taxol is the biggest at over $900 million in annual sales. I do not have the science background to understand how they work. My understanding is, in simplistic terms, that the patient is given a type of poison that hopefully poisons the tumors more quickly than the other vital tissues in the body. The hope for the investor in MGI-114 is that it will be more effective in that objective than other poisons out there.

As far as what is under development, there is also plenty of competition. You could spend hours, maybe days, on the Internet reviewing sights of clinical trials of cancer drugs. Here is one place to start:

graylab.ac.uk

Those who are involved in the MGI-114 trials say that it is the best cancer therapy currently under development. Sure, expect them to be biased, but it is exciting that MGI-114 is at least arguably the best thing in clinical trials.

BTW, I leave early tomorrow morning for a trade show and will be out of the loop until Wednesday.

Let's shrink some tumors!

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News